Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from JNJ

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Barchart

Why This Statistical Edge Favors CRWD, JNJ and LULU For the Coming Week

While narratives provide interesting context and color, empirical data delivers a quantitative advantage for astute options traders.

Barchart

3 Top Dividend Stocks Analysts Are Bullish on Right Now

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

Barchart

3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider

MarketBeat

3 Value Stocks Poised to Grow Dividends and Buybacks Now

As the U.S. and China agree to a 90-day tariff suspension, three value stocks stand out for their potential to compound returns through share buybacks and dividend growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Industry Behemoths Are Rewarding Investors With Dividend Bumps

See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.

MarketBeat

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

MarketBeat

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

MarketBeat

Earnings Preview: What to Expect From Johnson & Johnson's Report

Johnson & Johnson is all set to release its fiscal first-quarter earnings this month, and analysts project a single-digit profit decline.

Barchart

Stock Market Today: Stocks Are Mixed Before Liberation Day

Markets are getting into the freewheeling rhythm of a second Trump administration.

Kiplinger

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Barchart

Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

MarketBeat

3 Dividend-Paying Stocks Bucking the Market’s Trend

Despite a relentless market-wide selloff on Friday, Coca-Cola, Johnson & Johnson, and McDonald’s showed notable strength, defying the broader downtrend.

StockNews.com

3 "Forever Stocks" You Can Buy and Hold for Decades

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in the economic and geopolitical spheres. In this volatile environment, investors may find value in fundamentally stable stocks like Microsoft (MSFT), Alphabet (GOOGL), and Johnson & Johnson (JNJ). Continue to read….

StockNews.com

3 Defensive Stocks to Buy Before the Next Market Crash

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a market downturn manifests. Thus, fundamentally stable defensive stocks Walmart (WMT), UnitedHealth Group (UNH), and Johnson & Johnson (JNJ) might be ideal buys for defensive investing. Read on….

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Dividend Aristocrats With Consistent Payouts

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like consistent payouts, recession-proof, and risk protection. So, it could be wise to invest in dividend aristocrat stocks Johnson & Johnson (JNJ), PepsiCo (PEP), and Target (TGT) for substantial gains. Keep reading….

Barchart

Johnson & Johnson Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Johnson & Johnson's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

StockNews.com

3 Dividend Growth Stocks Perfect for Long-Term Investors

Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with strong financials, consistent dividend increases, and long-term growth potential: Johnson & Johnson (JNJ), PepsiCo (PEP), and Target (TGT). Read on.

Barchart

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

MarketBeat

Abbott Laboratories Will Outperform Healthcare Stocks in 2025

Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.

MarketBeat

MarketBeat Week in Review – 01/13 - 01/17

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

MarketBeat

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

1 2 3 4 5

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.